Literature DB >> 23065858

Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.

Jae Jun Park1, Ji-hee Kwon, Sun-Hee Oh, Junjeong Choi, Chang Mo Moon, Joong Bae Ahn, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Hoguen Kim, Won Ho Kim.   

Abstract

The association between the types of genomic instability and cancer stem cell (CSC) has not been elucidated. We aimed to investigate the expressions of CSC markers with respect to microsatellite instability (MSI) status in human colorectal cancer (CRC). Immunostainings for CD133, CD44, and CD166, and K-ras mutation analysis were performed on 50 MSI-high (MSI-H), and 50 microsatellite stable (MSS) CRC tissues. In 11 MSS and MSI-H CRC cell lines, CD133 expression and DNA methylation statuses of the CD133 promoter were determined. The proportion of CD133 positive cells and the ability of colosphere formation were compared between HCT116 cells and HCT116 + Chr3 cells (hMLH1-restored HCT116 cells). Immunohistochemistry for CSC markers revealed that high CD133 expression was more frequent in MSS cancers than in MSI-H (P < 0.001, 74.0% vs. 28.0%, respectively), and related with short disease-free survival. Neither CD44 nor CD166 expression differed significantly with respect to MSI status. K-ras mutation showed no association with expressions of CD133, CD44, or CD166. CD133 expression was relatively high in the MSS cell lines compared to those in MSI-H, and showed a reverse correlation with DNA methylation of the CD133 promoter. hMLH1-restored HCT116 cells increased proportions of CD133 positive cells and colosphere forming ability, compared to those in HCT116 cells. In conclusion, high levels of CD133 expression were observed more frequently in MSS CRC than in MSI-H, suggesting that differential expression of colon CSC markers may be linked to tumor characteristics dependent on MSI status.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD133; cancer stem cell; colorectal cancer; microsatellite instability

Mesh:

Substances:

Year:  2012        PMID: 23065858     DOI: 10.1002/mc.21971

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  The Association Between Inflammation, Epithelial Mesenchymal Transition and Stemness in Colorectal Carcinoma.

Authors:  Inese Briede; Ilze Strumfa; Andrejs Vanags; Janis Gardovskis
Journal:  J Inflamm Res       Date:  2020-01-08

2.  ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

Authors:  Leticia Elizabeth Augustin Czeczko; Carmen Australia Paredes Marcondes Ribas; Nicolau Gregori Czeczko; Thelma Larocca Skare; Camila Kienen Yamakawa; Guilherme Gionedis; Cecilia Vasconcelos; Fabiola Pabst Bremer; Diogo Francesco Castoldi; Martin Gasser; Ana Maria Waaga-Gasser
Journal:  Arq Bras Cir Dig       Date:  2021-03-22

3.  Prominin-1 and its role in tumor progression and assessment of clinical prognosis in systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

4.  Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.

Authors:  Fiorenza Lotti; Awad M Jarrar; Rish K Pai; Masahiro Hitomi; Justin Lathia; Adam Mace; Gerald A Gantt; Kumar Sukhdeo; Jennifer DeVecchio; Amit Vasanji; Patrick Leahy; Anita B Hjelmeland; Matthew F Kalady; Jeremy N Rich
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307

5.  DNA mismatch repair and CD133-marked cancer stem cells in colorectal carcinoma.

Authors:  Phaik-Leng Cheah; Jing Li; Lai-Meng Looi; Kean-Hooi Teoh; Diana Bee-Lan Ong; Mark J Arends
Journal:  PeerJ       Date:  2018-09-11       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.